SCHEDULE: Trinity Biotech plc: Perceptive Advisors Amends Schedule 13D

Perceptive Advisors LLC, along with its affiliates, has amended its Schedule 13D filing concerning Trinity Biotech plc, detailing changes to a convertible note and credit agreement.

Summary

• Perceptive Advisors LLC and its affiliated entities (Perceptive Credit Holdings II, L.P. and Perceptive Credit Holdings III, L.P.) have filed an amendment to their Schedule 13D regarding Trinity Biotech plc.
• The amendment details changes to a credit agreement and a convertible note, including a limited waiver of financial covenant non-compliance and an additional $2.5 million term loan.
• The convertible note was amended to increase the convertible amount from $60 million to $72.5 million and reduce the conversion price from $1.03 to $0.5061 per ADS.
• The filing reports a beneficial ownership of 9.9% of Trinity Biotech plc's Class A Ordinary Shares, representing 3,424,019,957 shares, based on 374,206,640 shares outstanding as of April 30, 2026.
• This ownership includes shares issuable from warrants, the amended convertible note, a milestone payment obligation, and a contingent payment obligation.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly negative. While the additional term loan is positive, the waiver of financial covenants suggests underlying financial stress, and the increased convertible note amount implies potential future dilution.

Positives

• The company secured an additional $2.5 million term loan, providing immediate capital.
• The amendment to the convertible note and credit agreement demonstrates a cooperative effort between Perceptive Advisors and Trinity Biotech plc to manage financial covenants and debt.
• The reduction in the conversion price of the convertible note to $0.5061 per ADS could make conversion more attractive for Perceptive Advisors under certain market conditions.

Negatives

• The filing indicates a limited waiver of financial covenant non-compliance, suggesting the company may have been struggling to meet certain financial obligations.
• The increase in the convertible note amount and the associated dilution potential for existing shareholders could be viewed negatively.

Risks

• The terms of the warrants, convertible note, and conversion rights agreement restrict exercise and conversion if beneficial ownership exceeds a 'Beneficial Ownership Cap', indicating potential limitations on future share acquisition.
• The company's reliance on Perceptive Advisors for financing and waivers suggests a potential dependence that could impact future strategic decisions.
• The potential for significant dilution exists if the convertible note and other obligations are fully converted into shares.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from Trinity Biotech plc. The future outlook is primarily shaped by the terms of the amended financial agreements and the potential conversion of debt into equity, which is subject to ownership caps.

Management Comments

• The Reporting Persons disclaim beneficial ownership of any Ordinary Shares, including those underlying ADSs, issuable upon exercise of warrants, conversion of the Milestone Payment Obligation, conversion of the Contingent Payment Obligation and conversion of the Convertible Note to the extent that upon such exercise or conversion the number of Ordinary Shares beneficially owned by all Reporting Persons hereunder, in the aggregate, would exceed the Beneficial Ownership Cap.

Industry Context

StockSavvy.ai notes that this filing reflects a common strategy in the biotechnology sector where companies often rely on specialized lenders and investors for financing, sometimes involving complex debt-to-equity conversion mechanisms. The amendment to the credit agreement and convertible note suggests ongoing financial restructuring or support, which is typical for companies in this industry navigating growth or operational challenges.

Comparison to Industry Standards

• In the biotechnology sector, it is not uncommon for companies to engage in debt financing with conversion features, similar to the Convertible Note and Milestone/Contingent Payment Obligations described. For instance, companies like Sorrento Therapeutics or MannKind Corporation have previously utilized convertible debt instruments.
• The reported beneficial ownership of 9.9% by a single entity (Perceptive Advisors and its affiliates) is significant but within the typical range for activist or major debt holders in mid-cap biotech firms, where stakes can range from 5% to over 20% for significant investors.
• The floor price of $0.5061 per ADS is a critical metric. In the biotech industry, such conversion prices are often set based on anticipated future valuations or previous financing rounds. This price point will be a key factor in determining the economic viability of conversion for the lender.

Related Party Transactions

• The transactions involve Perceptive Credit Holdings III, LP as the Administrative Agent for the credit agreement and as the holder of the Amended and Restated Note, and Perceptive Credit Holdings II, LP in relation to the Milestone Payment Obligation and Contingent Payment Obligation, all of which are related parties to the reporting entity Perceptive Advisors LLC.

Stakeholder Impact

• Shareholders: Potential for dilution due to the increased convertible note amount and the possibility of conversion into equity. The waiver of financial covenants may indicate financial instability, which could impact share price.
• Creditors: The amendment to the credit agreement and the additional term loan may affect the priority and terms for other creditors.
• Management: The company's financial performance is under scrutiny, as evidenced by the need for covenant waivers.

Next Steps

• Monitoring the conversion of the amended convertible note, milestone payment obligation, and contingent payment obligation into ADSs, subject to the Beneficial Ownership Cap.
• Observing Trinity Biotech plc's ability to meet its financial covenants going forward, especially after the limited waiver.
• Tracking the utilization of the additional $2.5 million term loan.

Key Dates

Recommendation

The filing indicates a complex financial situation for Trinity Biotech plc, with a need for covenant waivers and increased debt convertible into equity. While there's an injection of $2.5 million, the potential for significant dilution and the underlying financial pressures suggest a cautious 'hold' approach until the company demonstrates improved financial stability and operational performance.

Keywords

Trinity Biotech plc, Schedule 13D, Perceptive Advisors LLC, Convertible Note, Credit Agreement, Beneficial Ownership, ADS, Warrants, Amendment, SEC Filing